Fulcrum Therapeutics, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022. The filing was signed March 9, 2023. Fulcrum is a clinical-stage biopharmaceutical company developing treatments for genetically defined rare diseases; it has no product sales.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | $6.3 million | $19.2 million |
| Research and development expense | $76.8 million | $69.7 million |
| General and administrative expense | $41.7 million | $30.5 million |
| Net loss | $109.9 million | $80.8 million |
| Net loss per share | $2.44 | $2.29 |
| Net cash used in operating activities | $97.1 million | $78.5 million |
- Revenue was entirely collaboration revenue. The decrease primarily reflected lower revenue recognized from the Acceleron and MyoKardia collaborations.
- At December 31, 2022, cash, cash equivalents and marketable securities totaled $202.9 million, versus $218.2 million at year-end 2021. Current assets were $207.5 million and current liabilities $16.7 million.
- In January 2023, Fulcrum raised $117.3 million net in a common-stock offering. Management estimated that year-end liquidity plus these proceeds would fund operations and capital expenditures into mid-2025; this estimate depends on assumptions and may change.
- The filing reports no conventional borrowings. Total liabilities were $27.7 million, including $13.4 million of operating lease liabilities. The company reported an accumulated deficit of $412.3 million.
- As a pre-revenue company, Fulcrum reported operating losses rather than meaningful product margins.
Material changes and operating developments
- Net loss widened by $29.0 million year over year. Operating expenses rose $18.7 million, while collaboration revenue fell $12.8 million. R&D expense increased mainly with lead-program activity, including a $5.0 million GSK milestone for starting losmapimod’s Phase 3 REACH trial. G&A growth reflected higher employee compensation, including stock-based compensation, and facility costs.
- Operating cash use increased $18.6 million. Investing activities provided $12.4 million, primarily from net maturities of marketable securities; financing activities provided $84.3 million, mainly from the August 2022 stock offering.
- Acceleron elected to terminate its collaboration, effective October 1, 2022, and had not designated any targets. Fulcrum recognized $1.0 million of Acceleron revenue in 2022 versus $9.6 million in 2021. MyoKardia collaboration revenue was $5.3 million in 2022 versus $9.6 million in 2021.
- In August 2022, Fulcrum completed a workforce reduction equal to 25% of planned headcount to prioritize its two clinical programs; restructuring expense was $0.4 million.
Outlook, risks and unusual items
- Losmapimod: Phase 3 REACH for facioscapulohumeral muscular dystrophy (FSHD) began in Q2 2022. The planned trial enrolls approximately 230 adults and uses change in reachable workspace as its primary endpoint; enrollment was targeted for completion in the second half of 2023. The earlier Phase 2b trial did not meet its primary molecular endpoint, although the company reported favorable results on selected secondary and exploratory measures. These results do not establish Phase 3 success.
- FTX-6058: On February 23, 2023, after year-end, the FDA placed the sickle cell disease investigational application on full clinical hold, citing hematological malignancies observed in toxicology studies and similarities to risks reported with other PRC2 inhibitors. Fulcrum suspended enrollment and dosing and withdrew its separate beta-thalassemia IND. The filing states it is uncertain whether or when trials can resume. Early HbF increases were reported in small Phase 1b cohorts; these are preliminary data, not proof of clinical benefit.
- Fulcrum expects continued losses and substantial funding needs, with no assurance of profitability or access to future financing on acceptable terms. Further equity issuance could dilute shareholders. Clinical, regulatory, manufacturing, competitive, reimbursement and intellectual-property risks could delay or prevent development or commercialization.
- Other notable items: marketable securities had $0.8 million of gross unrealized losses at year-end, which the company did not consider other-than-temporary; no material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Key facts investors should verify
- Subsequent FDA communications and the status, requirements and potential timing for resolving the FTX-6058 clinical hold.
- REACH enrollment progress, endpoint performance, trial costs and any updated losmapimod development timeline.
- Actual quarterly cash burn and liquidity versus the mid-2025 runway estimate, including the effects of the January 2023 offering and future financing needs.
- Whether collaboration revenue, particularly from MyoKardia, continues and whether any milestones or royalties become payable.
- The scope and interpretation of FTX-6058 toxicology findings, and the clinical significance and safety of the preliminary HbF results.